Synergy in St. Louis

Backers of a new cluster of business incubators in St. Louis hope to make America's heartland a hotbed of new life sciences companies. Five venture capital funds are now operating in an area where risk capital was once a rarity. Three have raised more than $60 million to invest in technology and life sciences firms; two more plan to raise another $300 million. "It's astounding when you think about it-five funds trying to raise money at the same time, when our kind of money is very scarce in th

Written byPeg Brickley
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

"It's astounding when you think about it-five funds trying to raise money at the same time, when our kind of money is very scarce in the Midwest," says Brian Clevinger, managing director of Prolog Ventures LLC, a venture capital firm set up to invest in companies nurtured by the St. Louis incubators. "The synergy here in St. Louis suggests we all believe that something amazing is going on." A few years back, few venture capitalists focused their radar screens on St. Louis, even though area employers spend $2 billion annually on research and development. But the Midwestern city has redrawn the venture capital map in recent years thanks in part to an old idea--business incubation.

Incubators encourage scientists to take their dreams to the market by providing them a hub of new facilities equipped with state-of-the-art research laboratories and networks of experts to help develop business models. Incubator organizers increasingly ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies